We believe in pathogen inactivation and its potential to improve the safety of the global blood supply. This filing is one more step in our plan to commercialize the INTERCEPT Blood System for all three components: platelets, plasma, and red blood cells. |
We have made important progress over the past year. In 2005, we set very ambitious goals and I'm proud to say we've accomplished them all. As we move forward in blood safety and immunotherapy, I am confident our team is well positioned to successfully advance both programs. |